Check for updates

### G OPEN ACCESS

**Citation:** Jin X, Mi W (2017) Adenosine for postoperative analgesia: A systematic review and meta-analysis. PLoS ONE 12(3): e0173518. https:// doi.org/10.1371/journal.pone.0173518

Editor: Zheng-Liang Ma, Nanjing University Medical School Affiliated Nanjing Drum Tower Hospital, CHINA

Received: December 12, 2016

Accepted: February 21, 2017

Published: March 23, 2017

**Copyright:** © 2017 Jin, Mi. This is an open access article distributed under the terms of the <u>Creative</u> Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the paper and its Supporting Information files.

**Funding:** The author(s) received no specific funding for this work.

**Competing interests:** The authors have declared that no competing interests exist.

**RESEARCH ARTICLE** 

## Adenosine for postoperative analgesia: A systematic review and meta-analysis

#### Xin Jin<sup>©</sup>\*, Weidong Mi<sup>©</sup>

Department of Anesthesiology, Chinese PLA General Hospital, Beijing, China

• These authors contributed equally to this work.

\* why08317@163.com

## Abstract

#### Purpose

Perioperative infusion of adenosine has been suggested to reduce the requirement for inhalation anesthetics, without causing serious adverse effects in humans. We conducted a meta-analysis of randomized controlled trials evaluating the effect of adenosine on postoperative analgesia.

#### Methods

We retrieved articles in computerized searches of Scopus, Web of Science, PubMed, EMBASE, and Cochrane Library databases, up to July 2016. We used adenosine, postoperative analgesia, and postoperative pain(s) as key words, with humans, RCT, and CCT as filters. Data of eligible studies were extracted, which included pain scores, cumulative opioid consumption, adverse reactions, and vital signs. Overall incidence rates, relative risk (RR), and 95% confidence intervals (CI) were calculated employing fixed-effects or randomeffects models, depending on the heterogeneity of the included trials.

#### Results

In total, 757 patients from 9 studies were included. The overall effect of adenosine on postoperative VAS/VRS scores and postoperative opioid consumption was not significantly different from that of controls (P > 0.1). The occurrence of PONV and pruritus was not statistically significantly different between an adenosine and nonremifentanil subgroup (P > 0.1), but the rate of PONV occurrence was greater in the remifentanil subgroup (P < 0.01). Time to first postoperative analgesic requirement in the adenosine group was not significantly difference from that of the saline group (SMD = 0.07, 95%CI: -0.28 to 0.41, P = 0.71); but this occurred significantly later than with remifentanil (SMD = 1.10, 95%CI: 2.48 to 4.06, P < 0.01). Time to hospital discharge was not significantly different between the control and adenosine groups (P = 0.78). The perioperative systolic blood pressure was significantly lower in the adenosine than in the control group in the mannitol subgroup (P < 0.01). The incidence of bradycardia, transient first- degree atrioventricular block, and tachycardia was not significantly different between the adenosine and control groups (P > 0.1).

#### Conclusion

Adenosine has no analgesic effect or prophylactic effect against PONV, but reduce systolic blood pressure and heart rates. Adenosine may benefit patients with hypertension, ischemic heart disease, and tachyarrhythmia, thereby improving cardiac function.

#### Introduction

Postoperative pain can have a significant effect on patient recovery. The results of 1 survey have indicated that about 80% of patients who undergo surgery experience severe postoperative pain[1].Preemptive analgesia has therefore been widely used in the clinical setting; opioids remain the mainstay for postoperative analgesia, especially after major surgery[2]. However, opioid- related side-effects can be distressing to patients, and include respiratory depression, post-operative nausea and vomiting (PONV), urinary retention, sedation, and pruritus[3].To improve analgesic quality, adjunct medications are used; such multimodal analgesia allows more optimal pain management[4].

Adenosine(ADO) is a breakdown product of adenosine triphosphate(ATP); it is an endogenous purine nucleoside with several biological effects. It is involved in numerous biological processes, including neurotransmission, muscle contraction, heart function, and has antiinflammatory activity[5]. Perioperative infusion of low-dose adenosine in recent studies has been found to reduce the requirements for inhalation anesthetics[6]. It could be argued that the vasodilatory effect of ADO has a major influence on the stability of systolic blood pressure (SBP) during surgery. 2 groups with similar presurgical ET-ISO concentrations indicated the absence of significant ADO-induced reduction of SBP. This further implies that the maintained SBP reported in the ADO group during surgery is unrelated to an ADO-mediated vascular effect, but is rather due to an ADO-mediated modulation of the afferent reflex response to surgical trauma, which is related to the antinociceptive action of adenosine [6]To date, no serious adverse effects of ADO treatment have been reported in humans[6,7].

Here, we performed a meta-analysis to evaluate the impact of perioperative administration of ADO on postoperative pain, PONV, and the cardiovascular system.

#### Methods

We followed the recommendations of the PRISMA statement[8]

#### Search strategy

Published reports [2,6,7,9–16,] in English were retrieved in a computerized search of Scopus, Web of Science, PubMed, EMBASE, and Cochrane Library databases, for the period up to July 2016. The keywords used to search these databases were adenosine, postoperative analgesia and postoperative pain(s), and humans, RCT, and CCT were used as filters. We also examined similar published research with retrieved literatures.

#### Study selection

The details of the study selection processes are shown in Fig 1. The database search yielded 134 potentially relevant papers. However, 121 studies were excluded after reviewing the title and abstract as these included duplicated and non-original studies, while two were excluded as they did not meet the inclusion criteria; 11 studies were thus further investigated [2,6,7,9–16].

# 





A total of 448 patients who received ADO infusions and 403 controls were enrolled [2,6,7,9–16]. However, there were 2 studies in which the data were presented as bar graphs, and despite having contacted the corresponding authors, no further information could be obtained[10,11]. Therefore, eventually, only 9 studies were included [2,6,7,9, 12–16].

#### Data selection and extraction

**Inclusion criteria.** The criteria for inclusion of papers were as follows: (1) randomized assignment of patients to treatment groups, (2)double-blind assessments of pain and analgesic use, (3) report of pain using a reliable and valid measure, (4)report of analgesic consumption, (5)absence of obvious methodological problems.

The primary outcomes included postoperative pain scores and postoperative cumulative opioid consumption at 4h, 24 h, and 48h. Secondary outcomes included pain scores and opioid consumption at 4h, 24 h and, 48h, and adverse reactions (PONV and pruritus) at 1–24 h. Tertiary outcomes included patients' heart rate, blood pressure early, mid, and late during the surgical period. If results were not reported at the exact time-points specified above, those recorded closest to that time-point were used instead [17].

The eligible literature reports were assessed by 2 investigators, independently, according to the Cochrane Handbook guidelines. They extracted the following data: (1) surgical procedure, (2) mode,dose, and time-point of ADO administration, (3) number and gender of subjects, (4) American Society of Anesthesiologists grade, (5) primary outcome of the studies, (6) pain scores (rest/movement), (7) opioid consumption, and (8) adverse reactions (nausea, vomiting, pruritus, and sedation). If the data were presented as graphs/charts, the authors were contacted to provide specific data.

**Definition of outcomes.** Pain was rated using avisual analogue scale(VAS, range 0–10) or verbal/ numerical rating scale(VRS, range 0–100). We used the continuous data to obtain 95% confidence intervals(CIs) and the standardized mean differences (SMDs). If the 95% CIs included "0", it was implied that there was no statistically significance difference between treatment and control groups. We used dichotomous data to obtain relative risks (RRs); if the 95% CIs included "1," it also implied a lack of statistically significant difference between groups.

#### Data synthesis and analysis

All the analyses were conducted using Review Manager version 5.3 (Nordic Cochrane Centre, Copenhagen, Denmark). Heterogeneity was analyzed using the chi-square test. If P>0.1, which implied the absence of statistical heterogeneity among these studies, the fixed-effect (FE) model was applied to the meta-analysis. If P  $\leq$  0.1, I<sup>2</sup> was assessed. If I<sup>2</sup> > 50%, which implied significant heterogeneity, the random-effect (RE) model was applied to the meta-analysis. Sensitivity analysis and subgroup analysis were based on the primary outcome data. Publication bias was assessed by funnel plot and Egger test. We defined statistical significance by a 2-sided P < 0.05.

#### Results

#### Descriptions of the included randomized controlled trials

Four studies were conducted in Sweden[6,7,9,10], 2 studies in the USA [2,14], 2 studies in Turkey[11,12], 2 studies in India[13,16], and 1 study in Korea[15].6 studies included only female participants[2,7,9,10,13,16], while 5 studies included both male and female subjects [5,6,11,12,15].7 studies administered ADO via an intravenous route[2,6,7,9,12,14,15], and the remaining 4 studies did so via the intrathecal route [10,12,16]. The characteristics of these studies are summarized in Table 1, and risk of bias in these studies is summarized in Table 2.

#### Primary outcomes

**Pain scores at 4 h after surgery.** The overall effect of ADO on pain scores at 4 h after surgery, as compared with controls, showed no significant difference (SMD = -0.08, 95%CI: -0.26 to 0.10,  $I^2 = 53\%$ , P = 0.37),according to the forest plot (Fig 2). The funnel plot showed significant asymmetry (P < 0.05; Fig 3).

Drug categories in control group analysis In terms of the control group,3 studies used saline as placebo(saline subgroup) [2, 10, 16], 3 studies used ADO+mannitol in the treatment group and used only mannitol in the control group (mannitol subgroup)[6,7,9], and 2 studies used remifentanil as control (remifentanil subgroup) [14,15]. Compared with the ADO group, pain scores at 4 h after surgery in the saline (SMD = -0.01, 95%CI: -0.30 to 0.28, I<sup>2</sup> = 0%, P = 0.95) and mannitol (SMD = 0.08, 95%CI: -0.25 to 0.41,I<sup>2</sup> = 0%, P = 0.64) subgroups were similar; but the pain scores at 4 h after surgery in the remifentanil subgroup were higher (SMD = -1.40, 95%CI: -2.57 to -0.22, I<sup>2</sup> = 84%, P = 0.02). The analysis showed marked heterogeneity (I<sup>2</sup> = 84%, Fig 2).

*Drug- delivery route analysis* Four studies administered ADO by intravenous injection (IV subgroup) [2,6,7,9], 3 studies did so by intrathecal injection (IT subgroup) [10,16], and 2 studies used remifentanil as control(remifentanil subgroup) [14,15]. It was not possible to combine this group with the other studies, as they showed statistically significant heterogeneity. Compared with the ADO group, the pain scores at 4 h after surgery in the IV subgroup (SMD = 0.07, 95%CI: -0.20 to 0.34, I<sup>2</sup> = 0%, P = 0.61) and IT subgroup (SMD = -0.05, 95%CI: -0.41 to 0.32, I<sup>2</sup> = 0%, P = 0.81) were similar (Fig 2).

Sex subgroup analysis Six studies included only female patients(women subgroup) [2,6,7,9,11,13]. As the study by Ghai et al.[13]did not include the standard deviation for VAS pain scoring, it had to be excluded for the sake of accuracy. Compared with the ADO group, Sex in the women subgroup (SMD = -0.03, 95%CI: -0.20 to 0.26, I<sup>2</sup> = 0%, P = 0.78) was not statistically significantly different from a combined man/women subgroup (Fig 2).

**Pain scores at 24 h after surgery.** According to the overall forest plot for the effect of ADO on pain scores at 24 h after surgery, VAS/VRS scores in the treatment group was not significantly different from that in the control group (SMD = -0.03, 95%CI: -0.33 to 0.28, I<sup>2</sup> = 51%,P = 0.86; Fig 4). As only 6 studies investigated this time-point, the funnel plot was not suitable for evaluating publication bias.

Three studies used saline in the controls(saline subgroup) [2,10,16], two studies used ADO with mannitol in the treatment and mannitol in the control group (mannitol subgroup) [6,7,9]. Overall, these 5 studies were included in the non-remifentanil subgroup (nonremi). Two studies used remifentanil in the controls(remifentanil subgroup) [14,15].

Compared with the ADO group, VAS/VRS scores at 24 h after surgery in the nonremi (SMD = 0.08, 95%CI –0.15 to 0.31,  $I^2 = 0\%$ , P = 0.48) subgroup were not statistically significantly different between the ADO group and nonremi subgroup; however, these scores were higher in the remifertanil subgroup (SMD = -0.66, 95%CI: -0.18 to -0.14, P = 0.01).

**Pain scores at 48 h after surgery.** Only 1 study[2]examined the pain scores at 48 h after surgery s. In that study, there was no significant difference between the control group (a saline group) and the ADO group (P = 0.14).

**Cumulative postoperative opioid consumption.** The overall effect of ADO on early pain in terms of postoperative opioid consumption was not significantly different from that of control treatments (SMD = -0.74, 95%CI: -2.17 to 0.69,I<sup>2</sup> = 92%, P = 0.31) according to the forest

Table 1. Chai	acteri	stics o	of included s	studies	: (n = 757).								
First author/ year	Age (ys)	F/M	Number of patients (case/ control)	ASA	ADO dose	Surgery	Anesthesia method	ADO route	Primary outcome	second outcome	Intra- operative analgesia	PostoperativeAnalgesia	Case/ Control
Segerdahl M./1995	18– 70	70/0	70(36/34)	⊒	80 pg·kg <sup>-</sup> 1.min <sup>-1</sup>	Breast surgery	GA	.2	Pain scores	opioid consumption	02/N20/ ISO +ALF	MOR/CET	MAN +ADO/ MAN
Segerdahl M./1996	19– 62	7/23	30(14/16)	⊒	80 pg·kg <sup>-</sup> 1.min <sup>-1</sup>	Shoulder joint surgery	GA	.2	Pain scores	PONV (nausea)	02/N20/ ISO	MOR iv/im	MAN +ADO/ MAN
Segerdahl M./1997	32– 65	43/0	43(23/20)	⊒	80 pg·kg <sup>-</sup> 1.min <sup>-1</sup>	Abdominal hysterectomy	GA	.≥	Pain scores	opioid consumption	02/N20/ ISO +ALF/ FEN	MOR/KET iv	MAN +ADO/ MAN
Rane K./ 2000	37– 66	42/0	42(21/21)	Ξ	500 µg	Abdominal hysterectomy	GA	ij	Pain scores	opioid consumption	02/N20/ ISO+FEN	CET by PCA /after48h by OA	ADO/ SA
Apan A./ 2003	25 - 55	38/ 12	50(25/25)	⊒	80µg·kg <sup>-</sup> 1.min <sup>-1</sup>	Upper limb surgery	SA	it	Time to first complaint of pain	analgesic requirement	PRL/LGN	DIC	ADO/ SA
Apan A./ 2003	25– 55	44/ 18	60(30/30)	Ξ	80 µg·kg <sup>-</sup> <sup>1.</sup> min <sup>-1</sup>	Upper extremity surgery	BPB	Ś	Pain scores	opioid consumption	LD	MET iv	ADO/ SA
Ghai A./ 2011	40- 60	75/0	75(50/25)	Ī	500 µg/ 1000 µg	Vaginal hysterectomy	SA	ij	Sedation scores	Pain scores	FEN	FEN by PCA	ADO/ SA
Sharma M./ 2006	30- 60 -	0/06	90(60/30)	Ī	1000 µg	Abdominal hysterectomy	GA	it	Pain scores	Time to first rescue analgesia	02/N20/ HL+MOR	MORiv	Early (late) ADO/ SA
FukunagaA. F./2003	35 <sub>-</sub> 60	33/8	41(20/21)	⊒	50- 500 µg.kg <sup>-</sup> 1.min <sup>-1</sup>	Total abdominal hysterectom/ total knee arthroplasty/ total hip arthroplasty	GA	.2	Pain scores	Sedation scores	ADO/REM	MOR by PCA /FEN iv	ADO/ REM
Habib A. S./ 2008	18- 70	166/ 0	166(125/ 41)	≣	25, 50, 100, 200 µg·kg <sup>-</sup> 1.min <sup>-1</sup>	Major gynecologic surgery	GA	.2	Pain scores	opioid consumption	02/N20/ ISO+FEN	MOR/KET by PCA	ADO/ SA
Lee C./2011	30 - 20 -	39/ 51	90(30/60)	⊒	80 µg.kg <sup>-</sup> 1.min <sup>-1</sup>	Tonsillectomy	GA	.2	Pain scores	opioid consumption	REM/SEV	PET/KTR	ADO/ REM/ SEV
Ys = years, F/i plexus block, ř	M = fer v = intr	nales/r avenou	male, ASA = us injection; i	Americ it = intra	can Society of . athecal injectic	Anesthesiologists, m; im = intramuscu	ADO = adenos ular injection, P	ine, GA CA = pa	= general an tient-controll	esthesia, SA = 8 ed analgesia, IS	subarachnoid, O = isofluran	'spinal anesthesia, BPB = B ə, ALF = alfentanil, FEN = fe	rachial ntanil,

PRL = prilocaine, LGN = lignocaine, LD = Lidocaine, HL = halothane, MOR = morphine, REM = remifentanil, SEV = sevoflurane, CET = cetobemidone, KET = ketobemidone,

OA = oral analgesics, DIC = diclofenac, MET = metamizol, PET = pethidine, KTR = ketorolac, MAN = Isotonic mannitol, SA = saline

First author/ year	Adequate sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting
Segerdahl M./1995	LOW	LOW	LOW	LOW	LOW	LOW
Segerdahl M./1996	HIGH	LOW	LOW	LOW	LOW	LOW
Segerdahl M./1997	HIGH	LOW	LOW	UNCLEAR	LOW	LOW
Rane K./ 2000	LOW	LOW	LOW	LOW	LOW	LOW
Apan A./ 2003	LOW	LOW	HIGH	HIGH	LOW	LOW
Apan A./ 2003	LOW	LOW	LOW	LOW	LOW	LOW
Ghai A./2011	LOW	LOW	LOW	LOW	LOW	LOW
Sharma M./ 2006	LOW	HIGH	HIGH	HIGH	LOW	LOW
FukunagaA. F./ 2003	HIGH	HIGH	LOW	LOW	UNCLEAR	LOW
Habib A. S./ 2008	LOW	LOW	LOW	UNCLEAR	LOW	LOW
Lee C./2011	LOW	HIGH	HIGH	LOW	LOW	LOW

Table 2. Risk of bias.

Low = low risk of bias; unclear = unclear risk of bias; high = high risk of bias.

https://doi.org/10.1371/journal.pone.0173518.t002

plot (Fig 5). As this was recorded by only 6 studies, the funnel plot was not suitable for evaluating publication bias.

*Cumulative opioid consumption at 4h postoperatively* In terms of cumulative opioid consumption at 4 h, 3 studies were included: 2 for the nonremi subgroup [6,10] and 1 for the remifentanil subgroup [14].We show the cumulative opioid consumption at 4 h separately for these subgroups. In the nonremi subgroup, outcomes of the control groups were not significantly different from those of the ADO group (SMD = 0.04, 95%CI: -0.41 to 0.48,  $I^2 = 0\%$ , P = 0.88); in the remifentanil subgroup, the control group used significantly more opioids than did the ADO group (SMD = -2.35, 95%CI: -3.16 to -1.54, P < 0.00001).

*Cumulative opioid consumption at 24h postoperatively* The overall forest plot of cumulative opioid consumption at 24h showed that this value was statistically significantly higher for controls than for the ADO treatment group (SMD = -0.69, 95%CI-1.11 to -0.27, I<sup>2</sup> = 90%, P = 0.001; Fig 6). The funnel plot showed significant asymmetry (P < 0.05; Fig 7).

According to all impact factors, as previously stated, 3 studies were included in a saline subgroup [2,10,16];2 studies were included in a mannitol subgroup [7, 9];2 studies were included in the remifentanil subgroup [13,14]4 studies were included in the IV subgroup [2,6,7,9]; 3 studies were include in the IT subgroup [10,16]; and 6 studies were included in the women subgroup [2,6,7,9, 10,13]. Compared with ADO group, cumulative opioid consumption at 24h in the saline (P = 0.86), IT (P = 0.84), mannitol(P = 0.19), and women (P = 0.15) subgroups was not statistically significantly different between the treated subjects and controls; Nevertheless, in the remifentanil subgroup, the control group was administrated more opioid than the ADO treatment group (SMD = -1.45, 95%CI: -1.89 to -1.00, I<sup>2</sup> = 0%, P <0.00001).

*Cumulativeopioid consumption at 48h postoperatively* Two studies [2, 14] were included in the analysis of the cumulative opioid consumption at 48h. This value was significantly more

	ad	enosine	•	c	ontrols			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
2.1.1 saline									
Habib 2008	8.2	1.9	30	8.1	2	41	6.0%	0.05 [-0.42, 0.52]	
Rane 2000	36	18	18	32	24	18	4.4%	0.18 [-0.47, 0.84]	_ <del></del>
Sharma 2006	3.1	1.3	60	3.3	1.4	30	6.4%	-0.15 [-0.59, 0.29]	-
Subtotal (95% CI)			108			89	16.8%	-0.01 [-0.30, 0.28]	•
Heterogeneity: Tau <sup>2</sup> =	0.00; Cł	ni² = 0.79	9, df = :	2 (P = 0	.68); l² :	= 0%			
Test for overall effect:	Z = 0.06	(P = 0.9	95)						
2.1.2 mannitol									
Segerdahl 1995	43	16	36	40 5	20.5	34	6.1%	0 13 [-0 33, 0 60]	
segerdahl 1996	44	12	14	44	21	16	3.9%	0.00 [-0.72, 0.72]	
Segerdahl 1997	46.25	21.25	23	45.25	24.75	20	4.8%	0.04 [-0.56, 0.64]	_ <b>_</b> _
Subtotal (95% CI)			73			70	14.8%	0.08 [-0.25, 0.41]	<b>•</b>
Heterogeneity: Tau <sup>2</sup> =	0.00; Cł	ni² = 0.12	2, df = :	2 (P = 0	.94); l² :	= 0%			
Test for overall effect:	Z = 0.47	(P=0.6	64)						
2.1.3 remi							0.00/		
Fukunaga 2003	3.6	3.3	20	9	1.7	21	3.6%	-2.03 [-2.80, -1.27]	
Lee 2011 Subtotal (05% CI)	6	0.9	30	6.8	1	30	5.5%	-0.83 [-1.36, -0.30]	
Subiolal (95% CI)	0.61.04	- C 20	00 df =	1 (D = 0	01).12	010/	9.1%	-1.40 [-2.57, -0.22]	
Test for overall effect:	7 = 2.33	P = 0.3	9, ui – 12)	T (P = 0	.01), 1-	- 04 %			
rest for overall effect.	2 - 2.00	(1 – 0.0	52)						
2.1.4 intrathecal									
Rane 2000	36	18	18	32	24	18	4.4%	0.18 [-0.47, 0.84]	
Sharma 2006	3.1	1.3	60	3.3	1.4	30	6.4%	-0.15 [-0.59, 0.29]	-
Subtotal (95% CI)			78			48	10.8%	-0.05 [-0.41, 0.32]	•
Heterogeneity: Tau <sup>2</sup> =	0.00; Cł	$hi^2 = 0.69$	9, df =	1 (P = 0	.41); I² :	= 0%			
Test for overall effect:	Z = 0.24	(P = 0.8)	31)						
2 1 5 intravenous									
Habib 2008	82	1 0	30	8 1	2	41	6.0%	0.05 [-0.42, 0.52]	
Segerdahl 1995	43	1.5	36	40.5	20 5	34	6.1%	0.13 [-0.33, 0.60]	
segerdahl 1996	44	12	14	44	20.0	16	3.9%	0.00 [-0.72, 0.72]	
Segerdahl 1997	46.25	21.25	23	45.25	24.75	20	4.8%	0.04 [-0.56, 0.64]	_ <b>_</b>
Subtotal (95% CI)			103			111	20.9%	0.07 [-0.20, 0.34]	<b>•</b>
Heterogeneity: Tau <sup>2</sup> =	0.00; Cł	ni² = 0.12	2, df =	3 (P = 0	.99); l² :	= 0%			
Test for overall effect:	Z = 0.51	(P = 0.6	51)						
0.4.0									
2.1.6 women	0.0	10	20	0.4	0		0.00/	0.05 ( 0.40, 0.50)	
Habib 2008	0.2	1.9	10	0.1	2	41	0.0%		
Segerdabl 1995	30	10	36	3Z 40 5	24	34	4.4%	0.10 [-0.47, 0.04]	
Segerdahl 1995	46 25	21 25	23	45 25	20.0	20	4.8%	0.04 [-0.55, 0.60]	_ <b>_</b>
Sharma 2006	3 1	1.3	60	3.3	14	30	6.4%	-0.15 [-0.59 0.29]	
Subtotal (95% CI)	0.1	1.0	167	0.0	1.4	143	27.7%	0.03 [-0.20, 0.26]	<b>♦</b>
Heterogeneity: Tau <sup>2</sup> =	0.00; Cł	ni² = 1.0	5, df = -	4 (P = 0	.90); l²	= 0%			
Test for overall effect:	Z = 0.28	(P = 0.7	78)		,, , , , , , , , , , , , , , , , , , , ,				
Total (95% CI)			579			512	100.0%	-0.08 [-0.26, 0.10]	
Heterogeneity: Tau <sup>2</sup> =	0.08; Cł	ni² = 38.5	59, df =	= 18 (P =	= 0.003)	; l² = 5	3%		-2 -1 0 1 2
Test for overall effect:	Z = 0.90	(P = 0.3	37)					Fa	vours experimental Favours control
lest for subgroup diffe	erences:	$Chi^2 = 6$	.00, df	= 5 (P =	= 0.31),	I <sup>2</sup> = 16.	.6%		

Fig 2. Forest plot of pain scores at 4 h after surgery. SD = standard deviation; CI = confidence interval; MD = mean difference; W = weight; remi = remifentanil subgroups;  $I^2 = heterogeneity$ .

https://doi.org/10.1371/journal.pone.0173518.g002

PLOS ONE



https://doi.org/10.1371/journal.pone.0173518.g003

PLOS ONE

in the control than in the ADO group (SMD = -6.84, 95%CI: -14.72 to1.04, I<sup>2</sup> = 93%, P < 0.09, Fig 8). The heterogeneity in the data was higher, as one study [2] used saline in the controls (SMD = 0, 95%CI: -8.68 to 8.68); but the other study [17] used remifentanil in the controls (SMD = -39.00, 95%CI: -57.81 to -20.19). In the study by Fukunaga et al. [14], the usage of cumulative opioid consumption at 48 h was less in the ADO group than in the controls.

#### Secondary outcomes

**Postoperative nausea and vomiting.** Four studies examined the effect of ADO on PONV [2, 6,13, 14]. In 4 of these studies studies, except for that by Ghai et al. [13], nausea was combined with vomiting as a single outcome, while the other studies [2, 8, 14] considered them as separate outcomes.

*Postoperative nausea* Four studies were included in the analysis of nausea [2, 6, 13, 14]. The effect in the remifentanil subgroup suggested that postoperative nausea occurs significant more frequently in the control than in the ADO group (OR = 0.00 [0.00 to 0.07], P < 0.01;



	ad	enosine	Э	C	ontrols			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
2.2.1 mannitol+wome	n								
Habib 2008	8.2	1.8	30	8.2	1.9	41	18.4%	0.00 [-0.47, 0.47]	<b>+</b>
Rane 2000	21	13	18	14	7	18	12.6%	0.66 [-0.02, 1.33]	· · ·
Segerdahl 1995	20	17	36	21.25	18	34	18.4%	-0.07 [-0.54, 0.40]	
Segerdahl 1997	49.25	13.75	23	50.75	13.75	20	14.4%	-0.11 [-0.71, 0.49]	
Sharma 2006	3.1	1.4	60	2.9	1.3	30	19.5%	0.14 [-0.29, 0.58]	
Subtotal (95% CI)			167			143	83.3%	0.08 [-0.15, 0.31]	<b>•</b>
Heterogeneity: Tau <sup>2</sup> =	0.00; Cł	ni² = 3.7	8, df =	4 (P = 0	).44); l <sup>2</sup> :	= 0%			
Test for overall effect:	Z = 0.71	(P = 0.	48)						
2.2.2 remi									
Fukunaga 2003	0	0	0	0	0	0		Not estimable	
Lee 2011	2.1	0.6	30	2.5	0.6	30	16.7%	-0.66 [-1.18, -0.14]	
Subtotal (95% CI)			30			30	16.7%	-0.66 [-1.18, -0.14]	
Heterogeneity: Not app	olicable								
Test for overall effect:	Z = 2.48	(P = 0.	01)						
Total (95% CI)			197			173	100.0%	-0.03 [-0.33, 0.28]	<b>•</b>
Heterogeneity: Tau <sup>2</sup> =	0.07; Cł	ni² = 10.	30, df =	= 5 (P =	0.07); 1	² = 51%	þ		
Test for overall effect:	Z = 0.18	(P = 0.	86)					F	-1 -0.5 0 0.5 I
Test for subgroup diffe	rences:	Chi <sup>2</sup> = 6	6.52, df	= 1 (P =	= <b>0</b> .01),	l <sup>2</sup> = 84.	7%	Γc	avours experimental Favours control

Fig 4. Forest plot of pain scores at 24 h after surgery. SD = standard deviation; CI = confidence interval; MD = mean difference; W = weight; remi = remifentanil subgroups;  $I^2$  = heterogeneity.

https://doi.org/10.1371/journal.pone.0173518.g004

however, in the nonremi subgroup, there was no significant difference between the control and ADO group(P = 0.26; Fig 9).

*Postoperative vomiting* Two studies included an analysis of postoperative vomiting  $[2 \ 14]$ . The effect in the study by Fukunaga et al. (remifentanil subgroup) [14] suggested that this occurred significantly more frequently in the control than in the ADO group (OR = 0.03 [0.00

	ade	nosin	e	co	ontrols		5	Std. Mean Difference		Std. Me	an Diffe	rence	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% C		IV, Ra	ndom, 9	5% CI	
2.4.1 nonremi							-						
Rane 2000	11.5	3.75	24	11.25	4.75	24	34.3%	0.06 [-0.51, 0.62]			•		
segerdahl 1996	9.5	4	14	9.5	5	16	33.2%	0.00 [-0.72, 0.72]					
Subtotal (95% CI)			38			40	67.5%	0.04 [-0.41, 0.48]					
Heterogeneity: Tau <sup>2</sup> =	0.00; Cł	ni² = 0.	02, df =	= 1 (P =	0.90);	$ ^{2} = 0\%$	D						
Test for overall effect:	Z = 0.16	(P = (	0.88)										
2.4.2 remi													
Fukunaga 2003	7	6	20	24	8	21	32.5%	-2.35 [-3.16, -1.54]	l I				
Subtotal (95% CI)			20			21	32.5%	-2.35 [-3.16, -1.54]			1		
Heterogeneity: Not app	olicable												
Test for overall effect:	Z = 5.66	(P < (	0.0000	1)									
Total (95% CI)			58			61	100.0%	-0.74 [-2.17, 0.69]					2
Heterogeneity: Tau <sup>2</sup> =	1.46; Cł	ni² = 28	5.46, df	= 2 (P ·	< 0.00	001); l²	= 92%		100	50		<u> </u>	100
Test for overall effect:	Z = 1.02	(P = (	0.31)						Favoure	-50 ovnorimon	tal Fav	ours conti	
Test for subgroup diffe	erences:	Chi <sup>2</sup> =	25.45,	df = 1 (	P < 0.0	00001)	, l <sup>2</sup> = 96.1%	6	avours	experimen			UI I

Fig 5. Forest plot of cumulative opioid consumption at 4 h postoperatively. H = hour; SD = standard deviation; CI = confidence interval; MD = mean difference; W = weight; remi = remifentanil subgroups; nonremi = subgroups without remifentanil administration;  $I^2 = heterogeneity$ .

	ade	nosin	е	cc	ontrols			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% 0
2.5.1 remi									
Fukunaga 2003	53	26	20	92	35	21	5.5%	-1.24 [-1.91, -0.56]	
Lee 2011	35.2	4.3	30	47.1	9.4	30	5.6%	-1.61 [-2.19, -1.02]	
Subtotal (95% CI)			50			51	11.1%	-1.45 [-1.89, -1.00]	•
Heterogeneity: Tau <sup>2</sup> = Test for overall effect:	= 0.00; Ch : Z = 6.41	ni² = 0.0 (P < 0	66, df = 0.00001	= 1 (P = l)	0.42);	² = 0%	)		
2.5.2 mannitol									
Segerdahl 1995	15.6	8.7	36	20.6	11.3	35	5.9%	-0.49 [-0.96, -0.02]	
Segerdahl 1997	28.9	1.9	23	35.2	1.8	20	4.8%	-3.33 [-4.29, -2.38]	
Subtotal (95% CI)			59			55	10.7%	-1.88 [-4.67, 0.90]	
Heterogeneity: Tau² = Test for overall effect:	= 3.90; Cł : Z = 1.32	ni² = 27 (P = 0	7.50, df 0.19)	= 1 (P	< 0.000	001); I²	= 96%		
2.5.3 women									
Habib 2008	67	26	30	66	33	41	5.9%	0.03 [-0.44, 0.50]	+
Rane 2000	11.25	4.75	18	9.25	4	18	5.5%	0.45 [-0.22, 1.11]	T
Segerdahl 1995	15.6	8.7	36	20.6	11.3	35	5.9%	-0.49 [-0.96, -0.02]	
Segerdahl 1997	28.9	1.9	23	35.2	1.8	20	4.8%	-3.33 [-4.29, -2.38]	
01 0000	44 55	1 5	20	127	4 95	30	5.8%	-0 24 [-0 75 0 27]	
Sharma 2006	11.55	4.5	30	12.1	4.00		0.070	-0.24 [-0.73, 0.27]	
Sharma 2006 Subtotal (95% Cl) Heterogeneity: Tau² =	11.55 = 0.89: Ch	4.5	137 138 df	= 4 (P	< 0.00	<b>144</b> 001): l <sup>2</sup>	<b>27.8%</b>	-0.65 [-1.52, 0.23]	
Sharma 2006 Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 2 5 4 saline	= 0.89; Cł : Z = 1.45	4.5 hi² = 46 (P = 0	<b>137</b> 5.38, df 9.15)	= 4 (P	< 0.000	<b>144</b> 001); I <sup>2</sup>	<b>27.8%</b> = 91%	-0.65 [-1.52, 0.23]	
Sharma 2006 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 2.5.4 saline Habib 2008	11.55 = 0.89; Ch : Z = 1.45 67	4.5 1i <sup>2</sup> = 46 (P = 0	137 5.38, df 0.15)	= 4 (P	< 0.000	<b>144</b> 001); l <sup>2</sup>	27.8% = 91%	-0.65 [-1.52, 0.23]	
Sharma 2006 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 2.5.4 saline Habib 2008 Bane 2000	11.55 = 0.89; Ch : Z = 1.45 67 11 25	4.5 $h^2 = 46$ (P = 0) 26 4.75	30 137 5.38, df 0.15) 30 18	= 4 (P 66 9 25	< 0.000	<b>144</b> 001); l <sup>2</sup> 41	27.8% = 91% 5.9%	-0.65 [-1.52, 0.23] 0.03 [-0.44, 0.50]	
Sharma 2006 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 2.5.4 saline Habib 2008 Rane 2000 Sharma 2006	11.55 = 0.89; CF : Z = 1.45 67 11.25 11 55	4.5 hi <sup>2</sup> = 46 (P = 0 26 4.75	137 5.38, df 5.15) 30 18 30	66 9.25	<ul> <li>4.00</li> <li>33</li> <li>4</li> <li>4</li> <li>95</li> </ul>	<b>144</b> 001); I <sup>2</sup> 41 18 30	27.8% = 91% 5.9% 5.5%	-0.65 [-1.52, 0.23] -0.65 [-1.52, 0.23] 0.03 [-0.44, 0.50] 0.45 [-0.22, 1.11]	
Sharma 2006 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 2.5.4 saline Habib 2008 Rane 2000 Sharma 2006 Subtotal (95% CI)	11.55 = 0.89; CF : Z = 1.45 67 11.25 11.55	4.5 ii <sup>2</sup> = 46 (P = 0 26 4.75 4.5	137 5.38, df 0.15) 30 18 30 78	66 9.25 12.7	< 0.000 33 4 4.95	<b>144</b> 001); I <sup>2</sup> 41 18 30 <b>89</b>	5.9% 5.9% 5.5% 5.8% 17.2%	0.03 [-0.44, 0.50] 0.45 [-0.22, 1.11] -0.24 [-0.75, 0.27] 0.03 [-0.32, 0.38]	
Sharma 2006 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 2.5.4 saline Habib 2008 Rane 2000 Sharma 2006 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> =	11.55 = 0.89; Cr : Z = 1.45 67 11.25 11.55 = 0.02; Cr	4.5 (P = 0) (P = 0) 4.75 4.5 $hi^2 = 2.1$	137 5.38, df 5.15) 30 18 30 78 59, df =	66 9.25 12.7 = 2 (P =	< 0.000 33 4 4.95 0.27);	<b>144</b> 001); I <sup>2</sup> 41 18 30 <b>89</b> I <sup>2</sup> = 23	5.9% 5.5% 5.8% 17.2%	0.03 [-0.44, 0.50] 0.45 [-0.22, 1.11] -0.24 [-0.75, 0.27] 0.03 [-0.32, 0.38]	
Sharma 2006 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 2.5.4 saline Habib 2008 Rane 2000 Sharma 2006 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect:	11.55 = 0.89; Cr : Z = 1.45 67 11.25 11.55 = 0.02; Cr : Z = 0.18	4.5 $ii^2 = 46$ (P = 0) 4.75 4.5 $ii^2 = 2.3$ (P = 0)	137 5.38, df 0.15) 30 18 30 78 59, df = 0.86)	66 9.25 12.7 = 2 (P =	< 0.000 33 4 4.95 0.27);	<b>144</b> 001); I <sup>2</sup> 41 18 30 <b>89</b> I <sup>2</sup> = 23 <sup>1</sup>	5.9% 5.9% 5.5% 5.8% 17.2%	0.03 [-0.44, 0.50] 0.45 [-0.22, 1.11] -0.24 [-0.75, 0.27] 0.03 [-0.32, 0.38]	
Sharma 2006 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 2.5.4 saline Habib 2008 Rane 2000 Sharma 2006 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 2.5.5 intravenous	11.55 = 0.89; Cr : Z = 1.45 67 11.25 11.55 = 0.02; Cr : Z = 0.18	4.5 $ii^2 = 46$ (P = 0) 4.75 4.5 $ii^2 = 2.3$ (P = 0)	137 5.38, df 5.15) 30 18 30 78 59, df = 59, df = 5.86)	66 9.25 12.7 = 2 (P =	<ol> <li>33</li> <li>4.95</li> <li>0.27);</li> </ol>	144 001); I <sup>2</sup> 41 18 30 89 I <sup>2</sup> = 23 <sup>1</sup>	5.9% 5.9% 5.5% 5.8% 17.2%	0.03 [-0.44, 0.50] 0.45 [-0.22, 1.11] -0.24 [-0.75, 0.27] 0.03 [-0.32, 0.38]	
Sharma 2006 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 2.5.4 saline Habib 2008 Rane 2000 Sharma 2006 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 2.5.5 intravenous Habib 2008	11.55 = 0.89; Cr : Z = 1.45 67 11.25 11.55 = 0.02; Cr : Z = 0.18 67	4.5 $(P = 0)^{26}$ 4.75 4.5 $h^2 = 2.3$ $(P = 0)^{26}$	137 5.38, df 5.15) 30 18 30 78 59, df = 0.86) 30	66 9.25 12.7 = 2 (P =	<ul> <li>4.00</li> <li>33</li> <li>4.95</li> <li>0.27);</li> <li>33</li> </ul>	144 201); I <sup>2</sup> 41 18 30 89 I <sup>2</sup> = 23 <sup>1</sup>	5.9% 5.9% 5.5% 5.8% 17.2%	0.03 [-0.44, 0.50] 0.45 [-0.22, 1.11] -0.24 [-0.75, 0.27] 0.03 [-0.32, 0.38]	
Sharma 2006 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 2.5.4 saline Habib 2008 Rane 2000 Sharma 2006 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 2.5.5 intravenous Habib 2008 Segerdahl 1995	11.55 = 0.89; Cr : Z = 1.45 67 11.25 11.55 = 0.02; Cr : Z = 0.18 67 15.6	4.5 $ii^2 = 46$ (P = 0) 26 4.75 4.5 $ii^2 = 2.3$ (P = 0) 26 8.7	137 5.38, df 5.15) 30 18 30 78 59, df = 0.86) 30 36	66 9.25 12.7 = 2 (P = 66 20.6	<ul> <li>4.00</li> <li>33</li> <li>4.95</li> <li>0.27);</li> <li>33</li> <li>11.3</li> </ul>	144 201); I <sup>2</sup> 41 18 30 89 I <sup>2</sup> = 23' 41 35	5.9% 5.9% 5.5% 5.8% 17.2% %	0.03 [-0.44, 0.50] 0.45 [-0.22, 1.11] -0.24 [-0.75, 0.27] 0.03 [-0.32, 0.38] 0.03 [-0.44, 0.50] -0.49 [-0.96, -0.02]	
Sharma 2006 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 2.5.4 saline Habib 2008 Rane 2000 Sharma 2006 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 2.5.5 intravenous Habib 2008 Segerdahl 1995 segerdahl 1996	11.55 = 0.89; Cr : Z = 1.45 11.25 11.55 = 0.02; Cr : Z = 0.18 67 15.6 9.5	4.3 $(P = 0)^{26}$ 4.75 4.5 $(P = 0)^{26}$ $(P = 0)^{26}$ 8.7 4	137 5.38, df 0.15) 30 18 30 78 59, df = 0.86) 30 36 14	66 9.25 12.7 = 2 (P = 66 20.6 9.5	<ul> <li>33</li> <li>4.95</li> <li>0.27);</li> <li>33</li> <li>11.3</li> <li>5</li> </ul>	144 201); I <sup>2</sup> 41 18 30 89 I <sup>2</sup> = 23' 41 35 16	5.9% 5.9% 5.5% 5.8% 17.2% %	0.03 [-0.44, 0.50] 0.45 [-1.52, 0.23] 0.45 [-0.22, 1.11] -0.24 [-0.75, 0.27] 0.03 [-0.32, 0.38] 0.03 [-0.44, 0.50] -0.49 [-0.96, -0.02] 0.00 [-0.72, 0.72]	
Sharma 2006 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 2.5.4 saline Habib 2008 Rane 2000 Sharma 2006 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 2.5.5 intravenous Habib 2008 Segerdahl 1995 segerdahl 1996 Segerdahl 1997 Subtotal (95% CI)	11.55 = 0.89; Cr : Z = 1.45 11.25 11.55 = 0.02; Cr : Z = 0.18 67 15.6 9.5 28.9	4.5 $ii^2 = 46$ (P = 0) 4.75 4.5 $ii^2 = 2.1$ (P = 0) 26 8.7 4 1.9	137 5.38, df 0.15) 30 18 30 78 59, df = 0.86) 30 36 14 23 103	66 9.25 12.7 = 2 (P = 66 20.6 9.5 35.2	<ul> <li>4.00</li> <li>33</li> <li>4</li> <li>4.95</li> <li>0.27);</li> <li>33</li> <li>11.3</li> <li>5</li> <li>1.8</li> </ul>	144 001); I <sup>2</sup> 41 18 30 89 I <sup>2</sup> = 23 <sup>-</sup> 41 35 16 20 112	5.9% 5.5% 5.5% 5.8% 17.2% %	0.03 [-0.44, 0.50] 0.45 [-0.22, 1.11] -0.24 [-0.75, 0.27] 0.03 [-0.32, 0.38] 0.03 [-0.44, 0.50] -0.49 [-0.96, -0.02] 0.00 [-0.72, 0.72] -3.33 [-4.29, -2.38] -0.88 [-2.01, 0.24]	
Sharma 2006 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 2.5.4 saline Habib 2008 Rane 2000 Sharma 2006 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 2.5.5 intravenous Habib 2008 Segerdahl 1995 segerdahl 1996 Segerdahl 1997 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> =	11.55 = 0.89; Cr : Z = 1.45 11.25 11.55 = 0.02; Cr : Z = 0.18 67 15.6 9.5 28.9 = 1 19: Cr	4.5 $ii^2 = 46$ (P = 0) 4.75 4.5 $ii^2 = 2.1$ (P = 0) 26 8.7 4 1.9 $ii^2 = 40$	137 5.38, df 0.15) 30 18 30 78 59, df = 0.86) 30 36 14 23 103 103	= 4 (P 66 9.25 12.7 = 2 (P = 66 20.6 9.5 35.2 = 3 (P	<ul> <li>&lt; 0.000</li> <li>33</li> <li>4</li> <li>4.95</li> <li>0.27);</li> <li>33</li> <li>11.3</li> <li>5</li> <li>1.8</li> <li>&lt; 0.000</li> </ul>	144 001); I <sup>2</sup> 41 18 30 89 I <sup>2</sup> = 23 <sup>-</sup> 41 35 16 20 112 201); I <sup>2</sup>	5.9% 5.9% 5.5% 5.8% 17.2% % 5.9% 5.9% 5.9% 5.9% 5.4% 4.8% 21.9% = 93%	0.03 [-0.44, 0.50] 0.45 [-0.22, 1.11] -0.24 [-0.75, 0.27] 0.03 [-0.32, 0.38] 0.03 [-0.44, 0.50] -0.49 [-0.96, -0.02] 0.00 [-0.72, 0.72] -3.33 [-4.29, -2.38] -0.88 [-2.01, 0.24]	
Sharma 2006 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 2.5.4 saline Habib 2008 Rane 2000 Sharma 2006 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 2.5.5 intravenous Habib 2008 Segerdahl 1995 segerdahl 1995 segerdahl 1997 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect:	11.55 = 0.89; CF : Z = 1.45 67 11.25 11.55 = 0.02; CF : Z = 0.18 67 15.6 9.5 28.9 = 1.19; CF : Z = 1.55	4.3 $ii^{2} = 46$ $(P = 0)^{2}$ 4.75 4.75 4.5 $ii^{2} = 2.3$ $(P = 0)^{2}$ 26 8.7 4 1.9 $ii^{2} = 400$ $(P = 0)^{2}$	137 5.38, df 0.15) 30 18 30 78 59, df = 0.86) 30 36 14 23 103 0.83, df 0.12)	66 9.25 12.7 = 2 (P = 66 20.6 9.5 35.2 = 3 (P	<ul> <li>33</li> <li>4</li> <li>4.95</li> <li>0.27);</li> <li>33</li> <li>11.3</li> <li>5</li> <li>1.8</li> <li>&lt; 0.000</li> </ul>	144 201); I <sup>2</sup> 41 18 30 89 I <sup>2</sup> = 23' 41 35 16 20 112 201); I <sup>2</sup>	5.9% 5.9% 5.5% 5.8% 17.2% % 5.9% 5.9% 5.9% 5.9% 5.9% 5.4% 4.8% 21.9% = 93%	0.03 [-0.44, 0.50] 0.45 [-0.22, 1.11] -0.24 [-0.75, 0.27] 0.03 [-0.32, 0.38] 0.03 [-0.44, 0.50] -0.49 [-0.96, -0.02] 0.00 [-0.72, 0.72] -3.33 [-4.29, -2.38] -0.88 [-2.01, 0.24]	
Sharma 2006 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 2.5.4 saline Habib 2008 Rane 2000 Sharma 2006 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 2.5.5 intravenous Habib 2008 Segerdahl 1995 segerdahl 1995 segerdahl 1997 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 2.5.6 intrathecal	11.55 = 0.89; Cr : Z = 1.45 11.25 11.55 = 0.02; Cr : Z = 0.18 67 15.6 9.5 28.9 = 1.19; Cr : Z = 1.55	4.5 $ii^2 = 46$ (P = 0) 4.75 4.5 $ii^2 = 2.1$ (P = 0) 26 8.7 4 1.9 $ii^2 = 40$ (P = 0) (P = 0)	137 5.38, df 0.15) 30 18 30 78 59, df = 0.86) 30 36 14 23 103 0.83, df 0.12)	66 9.25 12.7 = 2 (P = 66 20.6 9.5 35.2 = 3 (P	<ul> <li>4.00</li> <li>33</li> <li>4.95</li> <li>0.27);</li> <li>33</li> <li>11.3</li> <li>5</li> <li>1.8</li> <li>&lt; 0.000</li> </ul>	144 201); I <sup>2</sup> 41 18 30 89 I <sup>2</sup> = 23 <sup>-</sup> 41 35 16 20 112 201); I <sup>2</sup>	5.9% 5.9% 5.5% 5.8% 17.2% % 5.9% 5.9% 5.9% 5.4% 4.8% 21.9% = 93%	0.03 [-0.44, 0.50] 0.45 [-0.22, 1.11] -0.24 [-0.75, 0.27] 0.03 [-0.32, 0.38] 0.03 [-0.44, 0.50] -0.49 [-0.96, -0.02] 0.00 [-0.72, 0.72] -3.33 [-4.29, -2.38] -0.88 [-2.01, 0.24]	
Sharma 2006 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 2.5.4 saline Habib 2008 Rane 2000 Sharma 2006 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 2.5.5 intravenous Habib 2008 Segerdahl 1995 segerdahl 1995 segerdahl 1997 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 2.5.6 intrathecal Rane 2000	11.55 = 0.89; Cr : Z = 1.45 11.25 11.55 = 0.02; Cr : Z = 0.18 67 15.6 9.5 28.9 = 1.19; Cr : Z = 1.55	4.5 $ii^2 = 46$ (P = 0) 4.75 4.5 $ii^2 = 2.1$ (P = 0) 26 8.7 4 1.9 $ii^2 = 40$ (P = 0) (P = 0) 4.75	137 5.38, df 0.15) 30 18 30 78 59, df = 0.86) 30 36 14 23 103 0.83, df 0.12)	<ul> <li>= 4 (P</li> <li>66</li> <li>9.25</li> <li>12.7</li> <li>= 2 (P =</li> <li>66</li> <li>20.6</li> <li>9.5</li> <li>35.2</li> <li>= 3 (P</li> <li>9.25</li> </ul>	<ul> <li>4.00</li> <li>33</li> <li>4.95</li> <li>0.27);</li> <li>33</li> <li>11.3</li> <li>5</li> <li>1.8</li> <li>&lt; 0.000</li> </ul>	144 201); I <sup>2</sup> 41 18 30 89 I <sup>2</sup> = 23 <sup>-</sup> 41 35 16 20 112 201); I <sup>2</sup> 18	5.9% 5.9% 5.5% 5.8% 17.2% % 5.9% 5.9% 5.4% 4.8% 21.9% = 93%	0.03 [-0.44, 0.50] 0.45 [-0.22, 1.11] -0.24 [-0.75, 0.27] 0.03 [-0.32, 0.38] 0.03 [-0.44, 0.50] -0.49 [-0.96, -0.02] 0.00 [-0.72, 0.72] -3.33 [-4.29, -2.38] -0.88 [-2.01, 0.24]	
Sharma 2006 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 2.5.4 saline Habib 2008 Rane 2000 Sharma 2006 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 2.5.5 intravenous Habib 2008 Segerdahl 1995 segerdahl 1995 segerdahl 1997 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 2.5.6 intrathecal Rane 2000 Sharma 2006	11.55 = 0.89; Cr : Z = 1.45 11.25 11.55 = 0.02; Cr : Z = 0.18 67 15.6 9.5 28.9 = 1.19; Cr : Z = 1.55 11.25	4.5 $ii^2 = 46$ (P = 0) 26 4.75 4.5 $ii^2 = 2.1$ (P = 0) 26 8.7 4 1.9 $ii^2 = 40$ (P = 0) 4.75 4.5	137 5.38, df 0.15) 30 18 30 78 59, df = 0.86) 30 36 14 23 103 0.83, df 0.12) 18 30 30 30 30 78 59, df = 0.86)	<ul> <li>12.7</li> <li>= 4 (P</li> <li>66</li> <li>9.25</li> <li>12.7</li> <li>= 2 (P =</li> <li>66</li> <li>20.6</li> <li>9.5</li> <li>35.2</li> <li>= 3 (P</li> <li>9.25</li> <li>12.7</li> </ul>	<ul> <li>4.00</li> <li>33</li> <li>4.95</li> <li>0.27);</li> <li>33</li> <li>11.3</li> <li>5</li> <li>1.8</li> <li>&lt; 0.000</li> <li>4</li> <li>4.95</li> </ul>	144 201); I <sup>2</sup> 41 18 30 89 I <sup>2</sup> = 23 <sup>-</sup> 41 35 16 20 112 201); I <sup>2</sup> 18 30	5.9% 5.9% 5.5% 5.8% 17.2% % 5.9% 5.9% 5.4% 4.8% 21.9% = 93% 5.5% 5.8%	0.03 [-0.44, 0.50] 0.45 [-0.22, 1.11] -0.24 [-0.75, 0.27] 0.03 [-0.32, 0.38] 0.03 [-0.32, 0.38] 0.00 [-0.72, 0.72] -3.33 [-4.29, -2.38] -0.88 [-2.01, 0.24] 0.45 [-0.22, 1.11] -0.24 [-0.75, 0.27]	

 Total (95% CI)
 475
 499
 100.0%
 -0.69
 [-1.11, -0.27]

 Heterogeneity: Tau<sup>2</sup> = 0.73; Chi<sup>2</sup> = 162.71, df = 17 (P < 0.00001); l<sup>2</sup> = 90%
 -0.69
 [-1.11, -0.27]
 -4
 -2
 0
 2
 4

 Test for overall effect: Z = 3.20 (P = 0.001)
 Test for subgroup differences: Chi<sup>2</sup> = 30.62, df = 5 (P < 0.0001), l<sup>2</sup> = 83.7%
 Favours experimental
 Favours control

Fig 6. Forest plot of cumulative opioid consumption at 24 h postoperatively. H = hour; SD = standard deviation; CI = confidence interval; MD = mean difference; W = weight; remi = remifentanil subgroups; nonremi = subgroups without remifentanil administration;  $I^2 = heterogeneity$ .

https://doi.org/10.1371/journal.pone.0173518.g006

PLOS ONE



https://doi.org/10.1371/journal.pone.0173518.g007

PLOS ONE

to 0.50]), but there was no significant difference between controls and the ADO group in the nonremi subgroup (Fig 10).

**Pruritus.** Only 1 study [2] analyzed the occurrence of pruritus; there was no significant difference between the control and ADO group (P = 0.54).

	ade	nosir	ne	CO	ntrol	s		Mean Difference	Mean Difference	ı
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95%	I IV, Fixed, 95% C	1
Fukunaga 2003	53	26	20	92	35	21	17.5%	-39.00 [-57.81, -20.19		
Habib 2008	29	18	30	29	19	41	82.5%	0.00 [-8.68, 8.68	-	
Total (95% CI)			50			62	100.0%	-6.84 [-14.72, 1.04]	•	
Heterogeneity: Chi <sup>2</sup> = Test for overall effect:	13.61, df Z = 1.70	<sup>r</sup> = 1 ( (P =	P = 0.0 0.09)	002); l²	= 93	%			-100 -50 0 Favours experimental Favours	50 100 s control

Fig 8. Forest plot of cumulative opioid consumption at 48 h postoperatively. H = h; SD = standard deviation; CI = confidence interval; MD = mean difference;  $I^2$  = heterogeneity.

	adenos	ine	contro	ls		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% Cl
2.7.1 nonremi							
Ghai 2011	13	25	13	25	16.4%	1.00 [0.33, 3.03]	-+-
Habib 2008	18	30	29	41	25.7%	0.62 [0.23, 1.68]	
segerdahl 1996	1	14	4	16	9.1%	0.23 [0.02, 2.37]	
Subtotal (95% CI)		69		82	51.2%	0.67 [0.34, 1.35]	•
Total events	32		46				
Heterogeneity: Chi <sup>2</sup> = 1	l.33, df = 2	2 (P = 0	.51); l² =	0%			
Test for overall effect: 2	Z = 1.12 (I	P = 0.26	5)				
2.7.2 remi							
Fukunaga 2003	0	20	19	21	48.8%	0.00 [0.00, 0.07]	<b>←</b>
Subtotal (95% CI)		20		21	48.8%	0.00 [0.00, 0.07]	
Total events	0		19				
Heterogeneity: Not app	licable						
Test for overall effect: 2	Z = 3.65 (I	P = 0.00	003)				
Total (95% CI)		89		103	100.0%	0.35 [0.19, 0.62]	•
Total events	32		65				
Heterogeneity: Chi <sup>2</sup> = 1	3.82, df =	3 (P =	0.003); l <sup>2</sup>	= 78%			
Test for overall effect: 2	Z = 3.57 (I	P = 0.00	004)			<b>E</b> /	0.001 0.1 1 10 1000
Test for subgroup diffe	rences: C	hi² = 10	.99, df = '	1 (P = (	0.0009), I <sup>2</sup>	= 90.9%	

Fig 9. Forest plot of effect on postoperative nausea.  $CI = confidence interval; remi = remifentanil subgroups; nonremi = subgroups without remifentanil administration; <math>I^2 = heterogeneity; M-H = Mantel-Haenszel.$ 

https://doi.org/10.1371/journal.pone.0173518.g009

**Time to first postoperative analgesic requirement.** Three studies were included in the analysis of the time to first postoperative analgesic requirement (min); there were 2 studies in the saline subgroup [2, 16] and 1 study in the remifentanil subgroup [15]. In the saline subgroup, this outcome was not significantly different in the control compared to the ADO group (SMD = 0.07, 95%CI: -0.28 to 0.41, I<sup>2</sup> = 0%, P = 0.71); in the remifentanil subgroup, this occurred significantly earlier in the control than in the ADO group (SMD = 1.10, 95%CI: 2.48 to 4.06, P < 0.01; Fig 11).

**Time to hospital discharge.** Only the study by Habib et al. [2] observed the effect of ADO in time for hospital discharge. They found no significant difference between the control group with the ADO group(P = 0.78).

**Effects on cardiovascular system.** We assessed the overall effects of ADO on the cardiovascular system, as compared with the control and treatment; several aspects were considered,

	adenosi	ine	contro	ols		Odds Ratio	Odds Ratio	
Study or Subgroup	Events	Total	<b>Events</b>	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl	
Fukunaga 2003	0	20	10	21	79.4%	0.03 [0.00, 0.50] 🛛 🕂		
Habib 2008	7	30	4	41	20.6%	2.82 [0.74, 10.69]	+	
Total (95% CI)		50		62	100.0%	0.60 [0.24, 1.47]	•	
Total events	7		14					
Heterogeneity: Chi <sup>2</sup> = 9	9.50, df = 1	(P = 0	).002); l <sup>2</sup> :	= 89%				+
Test for overall effect:	Z = 1.12 (P	P = 0.26	6)			Favours	s experimental Favours control	)

Fig 10. Forest plot of effect on postoperative vomiting. CI = confidence interval; I<sup>2</sup> = heterogeneity; M-H = Mantel-Haenszel.



	ade	nosir	ne	co	ntrols	5	S	td. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	I IV, Fixed, 95% CI
2.11.1 nonremi									
Habib 2008	1,464	63	30	1,459	122	41	45.0%	0.05 [-0.42, 0.52]	+
Sharma 2006	471	424	30	437	352	30	38.9%	0.09 [-0.42, 0.59]	
Subtotal (95% CI)			60			71	84.0%	0.07 [-0.28, 0.41]	•
Heterogeneity: Chi <sup>2</sup> = 0	).01, df :	= 1 (P	= 0.92	); I <sup>2</sup> = 0 <sup>6</sup>	%				
Test for overall effect: 2	Z = 0.38	(P =	0.71)						
2.11.2 remi									
Lee 2011	66.1	9.1	30	39.2	7	30	16.0%	3.27 [2.48, 4.06]	
Subtotal (95% CI)			30			30	16.0%	3.27 [2.48, 4.06]	
Heterogeneity: Not app	olicable								
Test for overall effect: 2	Z = 8.12	(P <	0.0000	1)					
Total (95% CI)			90			101	100.0%	0.58 [0.26, 0.90]	$\blacklozenge$
Heterogeneity: Chi <sup>2</sup> = 5	53.21, di	f = 2 (	P < 0.0	0001); I	² = 96	%			
Test for overall effect: 2	Z = 3.60	(P =	0.0003	)					-4 -2 U 2 4
Test for subgroup diffe	rences:	Chi <sup>2</sup> =	= 53.20	, df = 1	(P < 0	.00001	), I <sup>2</sup> = 98.1 <sup>9</sup>	%	avours experimental Favours control

Fig 11. Forest plot of effect on time to first postoperative analgesic requirement (in minutes).  $CI = confidence interval; I^2 = heterogeneity; M-H = Mantel-Haenszel; remi = remifentanil subgroups.$ 

https://doi.org/10.1371/journal.pone.0173518.g011

as follows: systolic blood pressures (SBp), diastolic blood pressures (DBp), heart rate (HR), bradycardia, tachycardia, and transient first -degree atrio-ventricular block (AVB.)

Systolic and diastolic blood pressures Both SBP and DBP at different surgical stages were evaluated to determine the effects of ADO on blood pressure. The surgical processes were divided into 3 parts: early surgical period, mid-surgical period, and late surgical period.;. For assessing SBP, 4 studies were eligible;3 studies were includedin mannitol subgroup [6, 7, 9], and only1study[10] was included in the IT+ saline subgroup. The early SBP was significantly lower in the ADO than the control group in the mannitol subgroup (SMD = -19.26, 95%CI:-21.37 to -17.14, I<sup>2</sup> = 88%, P <0.01), while early SBP was similar between the A-DO and the control group in the IT+saline subgroup (SMD = 7.00, 95%CI: -0.95 to 14.95, P = 0.08, Fig 12).

For assessing SBP in the mid-surgical period, 5 studies were eligible; 3 studies were included in the mannitol subgroup [6, 7, 9], 1 study[2] in the IV+ saline subgroup, and 1 study[10] in the IT+ saline subgroup. The SBP was significantly lower in the ADO group than in the controls in the mannitol (SMD = -17.27, 95%CI: -18.68 to -15.86, I<sup>2</sup> = 0%, P <0.01) and IV + saline(SMD = -16.00, 95%CI: -22.07 to -9.93, P <0.00001) subgroups; while the SBP was similar between ADO treatment and control groups in the IT+saline subgroup (SMD = 0.00, 95%CI:-7.69 to 7.69, P = 1.00; Fig 13).

For SBP in the late surgical period, the studies included and the trends of the outcome were almost the same as for the early SBP (Fig 14).

For DBP, only 1 study [2] could be assessed. The study [2] was included in the IV+ saline subgroup. The DBP in the ADO group was significant lower than that in the controls (SMD = -17.00, 95%CI: -21.91 to -12.09, P < 0.01).

One study [18] was included in the analysis of hypotension; this study used remifertanil as the control. There was no significant differences between the ADO and control groups (P = 0.15).

*Heart rate* We also considered the effect of ADO on HR in to 3 parts: early surgical period, mid-surgical period, and late surgical period.separately. For early HR,3 studies were eligible;2



	ade	nosir	ne	со	ntrol	s		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% (	IV, Fixed, 95% CI
2.12.1 mannitol							-		
Segerdahl 1995	89	14	36	104	21	34	5.9%	-15.00 [-23.41, -6.59]	
segerdahl 1996	93	4.6	14	108	4	16	43.3%	-15.00 [-18.11, -11.89]	
Segerdahl 1997	103	4.8	23	127	5.4	20	44.2%	-24.00 [-27.07, -20.93]	
Subtotal (95% CI)			73			70	93.4%	-19.26 [-21.37, -17.14]	•
Heterogeneity: Chi <sup>2</sup> =	17.35, df	= 2 (	P = 0.0	002); l²	= 88	%			
Test for overall effect:	Z = 17.8	5 (P •	< 0.000	01)					
2.12.2 IT+saline									
Rane 2000	100	14	18	93	10	18	6.6%	7.00 [-0.95, 14.95]	
Subtotal (95% CI)			18			18	6.6%	7.00 [-0.95, 14.95]	
Heterogeneity: Not ap	plicable								
Test for overall effect:	Z = 1.73	(P =	0.08)						
Total (95% CI)			91			88	100.0%	-17.52 [-19.57, -15.48]	•
Heterogeneity: Chi <sup>2</sup> =	56.51, df	= 3 (	P < 0.0	0001);	² = 9	5%			
Test for overall effect:	Z = 16.8	1 (P •	< 0.000	01)					-20 -10 0 10 20
Test for subgroup diffe	erences:	Chi <sup>2</sup> :	= 39.16	, df = 1	(P <	0.0000	1), l <sup>2</sup> = 97	.4%	Favours experimental Favours control

**Fig 12.** Forest plot of effect on systolic blood pressure in the early surgical period. CI = confidence interval; IV = intravenous injection; IT = intrathecal injection; I<sup>2</sup> = heterogeneity, early = early surgical period; SBP = systolic blood pressure.

https://doi.org/10.1371/journal.pone.0173518.g012

	ade	nosir	ie	co	ntrol	s		Mean Difference	м	ean Diffe	rence	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	I IV	, Fixed, S	95% CI	
2.13.1 mannitol												
Segerdahl 1995	88	17	36	102	17	34	2.9%	-14.00 [-21.97, -6.03]		-		
segerdahl 1996	85	3.4	12	103	2.6	15	33.7%	-18.00 [-20.33, -15.67]		•		
Segerdahl 1997	92	2.7	23	109	3.3	20	55.3%	-17.00 [-18.82, -15.18]				
Subtotal (95% CI)			71			69	91.9%	-17.27 [-18.68, -15.86]		•		
Heterogeneity: Chi <sup>2</sup> =	1.11, df :	= 2 (P	= 0.57	); I² = 0	%							
Test for overall effect:	Z = 23.9	9 (P ·	< 0.000	01)								
	400	40	20	440		44	F 00/	40.001.00.07 0.001				
Habib 2008 Subtotal (05% CI)	102	12	30	118	14	41	5.0%	-16.00 [-22.07, -9.93]				
Subtotal (95% CI)	aliaabla		30			41	5.0%	-10.00 [-22.07, -9.93]		•		
Test for overall offect:	pilcable 7 - 5 17	(D <	0 0000	1)								
Test for overall effect.	2 - 5.17	(Г <	0.0000	1)								
2.13.3 IT+saline												
Rane 2000	104	14	18	104	9	18	3.1%	0.00 [-7.69, 7.69]		+		
Subtotal (95% CI)			18			18	3.1%	0.00 [-7.69, 7.69]		•		
Heterogeneity: Not app	plicable											
Test for overall effect:	Z = 0.00	(P =	1.00)									
										.		
Total (95% CI)			119			128	100.0%	-16.67 [-18.03, -15.32]		•		
Heterogeneity: Chi <sup>2</sup> =	19.91, di	= 4 (	P = 0.0	005); l²	= 80	%			-100 -50		50	100
Test for overall effect:	Z = 24.1	5 (P •	< 0.000	01)					Favours experin	nental E	avours contre	n oon
Test for subaroup diffe	erences:	Chi <sup>2</sup> =	= 18.80	. df = 2	(P < I)	0.0001	), $ ^2 = 89.4$	1%		ional io		

Fig 13. Forest plot of effect on systolic blood pressure in the mid-surgical period. CI = confidence interval; IV = intravenous injection; IT = intrathecal injection; I<sup>2</sup> = heterogeneity, mid = mid-surgical period; SBP = systolic blood pressure.



	ade	ne	со	ntrol	s		Mean Difference	Mean Difference			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% (	I IV, Fixed, 95% CI		
2.12.1 mannitol							-				
Segerdahl 1995	88	14	36	94	14	34	7.0%	-6.00 [-12.56, 0.56	-		
segerdahl 1996	84	4.1	11	107	3	12	34.2%	-23.00 [-25.96, -20.04]			
Segerdahl 1997	96	3.8	23	111	3.9	20	56.1%	-15.00 [-17.31, -12.69]			
Subtotal (95% CI)			70			66	97.3%	-17.17 [-18.92, -15.42]	•		
Heterogeneity: Chi <sup>2</sup> =	29.44, df	= 2 (	P < 0.0	0001);	<sup>2</sup> = 9	3%					
Test for overall effect:	Z = 19.1	8 (P <	< 0.000	01)							
2.12.2 IT+saline											
Rane 2000	115	18	18	115	14	18	2.7%	0.00 [-10.53, 10.53]	<u>+</u>		
Subtotal (95% CI)			18			18	2.7%	0.00 [-10.53, 10.53]	•		
Heterogeneity: Not ap	plicable										
Test for overall effect:	Z = 0.00	(P =	1.00)								
Total (95% CI)			88			84	100.0%	-16.71 [-18.44, -14.98]	•		
Heterogeneity: Chi <sup>2</sup> =	39.37, df	= 3 (	P < 0.0	0001);	<sup>2</sup> = 9	2%					
Test for overall effect:	Z = 18.9	2 (P <	< 0.000	01)					-100 -50 0 50 100		
Test for subgroup diffe	erences:		Favours experimental Favours control								

**Fig 14.** Forest plot of effect on systolic blood pressure in the late surgical period. CI = confidence interval; IV = intravenous injection; IT = intrathecal injection; I<sup>2</sup> = heterogeneity, late = late surgical period; SBP = systolic blood pressure.

https://doi.org/10.1371/journal.pone.0173518.g014

studies were included in the mannitol subgroup [6, 7],and only 1 study[10] was included in the IT+saline subgroup. The early HR in the ADO group was not significantly different from that in the control group in the mannitol (P = 0.20) of IT+ saline subgroups (P = 0.10; Fig 15).

For evaluating mid HR, we included 4 studies. 2 studies were included in the mannitol subgroup [6, 7], and 1 study[2] was included in the IV+ saline subgroup and one study[10] in the IT+ saline subgroup. The mid HR in the ADO group was not statistically significantly different from that in the control group in the mannitol(P = 0.74) and IT+ saline subgroups (P = 0.27);

	ade	nosir	e	со	ntrol	s		Mean Difference	Mean Differ	ence
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	I IV, Fixed, 9	5% CI
2.15.1 mannitol										
segerdahl 1996	105	5.7	14	100	4.4	16	21.8%	5.00 [1.32, 8.68]		
Segerdahl 1997	86	2.8	23	86	3.8	20	72.3%	0.00 [-2.02, 2.02]		
Subtotal (95% CI)			37			36	94.1%	1.16 [-0.61, 2.93]	•	
Heterogeneity: Chi <sup>2</sup> = 5	5.44, df =	= 1 (P	= 0.02	2); l <sup>2</sup> = 8	2%					
Test for overall effect:	Z = 1.28	(P =	0.20)							
2.15.2 IT+saline										
Rane 2000	64	8	18	70	13	18	5.9%	-6.00 [-13.05, 1.05]		
Subtotal (95% CI)			18			18	5.9%	-6.00 [-13.05, 1.05]	•	
Heterogeneity: Not app	olicable									
Test for overall effect:	Z = 1.67	(P =	0.10)							
Total (95% CI)			55			54	100.0%	0.73 [-0.99, 2.45]	!	
Heterogeneity: Chi <sup>2</sup> = 9	9.16, df =	= 2 (P	= 0.01	);  ² = 7	8%					50 100
Test for overall effect:	Z = 0.84	(P =	0.40)					1	-100 -30 0 Favours experimental Fa	vours control
Test for subgroup diffe	rences:	avours experimental 1 a								

**Fig 15.** Forest plot of effect on heart rate in the early surgical period. CI = confidence interval; IV = intravenous injection; IT = intrathecal injection; I<sup>2</sup> = heterogeneity, early = early surgical period; HR = heart rate.



	adenosine controls							Mean Difference	Mean Difference			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	I IV, Fixed, 95% CI			
2.16.1 mannitol												
segerdahl 1996	94	4.7	12	93	3.3	15	24.0%	1.00 [-2.14, 4.14]	*			
Segerdahl 1997	80	2.8	23	80	3.6	20	62.3%	0.00 [-1.95, 1.95]	<b>.</b>			
Subtotal (95% CI)			35			35	86.2%	0.28 [-1.38, 1.93]	•			
Heterogeneity: Chi <sup>2</sup> = 0	).28, df =	= 1 (P	= 0.60	); I <sup>2</sup> = 0	%							
Test for overall effect: 2	Z = 0.33	(P =	0.74)									
2.16.2 IV+saline												
Habib 2008	80	10	30	72	12	41	9.0%	8.00 [2.87, 13.13]				
Subtotal (95% CI)			30			41	9.0%	8.00 [2.87, 13.13]	•			
Heterogeneity: Not app	licable											
Test for overall effect: 2	Z = 3.06	(P =	0.002)									
2.16.3 IT+saline												
Rane 2000	66	8	18	70	13	18	4.8%	-4.00 [-11.05, 3.05]				
Subtotal (95% CI)			18			18	4.8%	-4.00 [-11.05, 3.05]	•			
Heterogeneity: Not app	licable											
Test for overall effect: 2	Z = 1.11	(P =	0.27)									
Total (95% CI)			83			94	100.0%	0.77 [-0.77, 2.31]				
Heterogeneity: Chi <sup>2</sup> = 1	0.01, df	= 3 (	P = 0.0	2); l² =	70%				-100 -50 0 50 100			
Test for overall effect: 2	Z = 0.98	(P =	0.33)						Favours experimental Favours control			
Test for subgroup diffe	rences:	Chi <sup>2</sup> =	= 9.73,	df = 2 (I	<b>P</b> = 0	.008), l <sup>a</sup>	<sup>2</sup> = 79.5%					

Fig 16. Forest plot of effect on heart rate in the mid-surgical period. CI = confidence interval; IV = intravenous injection; IT = intrathecal injection; I<sup>2</sup> = heterogeneity, mid = mid-surgical period; HR = heart rate.

https://doi.org/10.1371/journal.pone.0173518.g016

however, the mid HR was higher in the ADO group than in the control group in the IV+ saline subgroup (P = 0.002; Fig 16).

For assessing HR in late surgical period, 3 studies were included: 2 studies were included in the mannitol subgroup[6, 7],while 1 study[10] was included in the IT+ saline subgroup. The HR was significant higher in the ADO group than in the control group in the mannitol subgroup (SMD = 4.06, 95%CI:2.37 to 5.74, P <0.00001). However, the late HR in the IT+ saline subgroup was not significantly different between the treatment and control groups (P = 0.12; Fig 17).

For both bradycardia and transient first degree AVB, two studies [2, 15] were eligible for inclusion. 1 study [2] was included in the IV+ saline subgroup, but the study of Lee et al. [15] used remifentanil in the controls. The incidence of bradycardia (P = 0.24) and transient first degree AVB (P = 0.17) was not significantly different in the ADO than in the control groups (Figs 18 and 19).For tachycardia evaluation, 1 study [2] was in it. However, the comparison between ADO and control was not significantly different.

#### Discussion

This meta-analysis suggested that ADO administration did not change postoperative VAS/ VRS scores by 24 h, irrespective of sex, or whether it was administered by IT or IV, or with mannitol. In comparison with remifentanil, ADO reduced postoperative pain by 24 h, and reduced opioid consumption over the first 48 h; however, in comparison with other non-remifentanil control treatments, ADO had no significant effect on pain score or opioid consumption. Moreover, the time to first analgesic requirement was much earlier in remifentaniltreated than in the ADO group, but ADO treatment did not differ from saline treatment in



	adenosine controls					fference							
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95%	CI	IV, Fixe	d, 95% Cl	I	
2.17.1 mannitol													
Segerdahl 1997	93	4.4	11	95	3.9	12	23.2%	-2.00 [-5.41, 1.41	]		<u>L</u>		
segerdahl 1996	80	2.4	23	74	3.8	20	72.1%	6.00 [4.07, 7.93	]				
Subtotal (95% CI)			34			32	95.3%	4.06 [2.37, 5.74	1		•		
Heterogeneity: Chi <sup>2</sup> =	16.00, df	f = 1 (	P < 0.0	0001); l²	= 94	%							
Test for overall effect:	Z = 4.73	(P <	0.0000	1)									
2.17.2 IT+saline													
Rane 2000	69	10	18	75	13	18	4.7%	-6.00 [-13.58, 1.58	]	-	t		
Subtotal (95% CI)			18			18	4.7%	-6.00 [-13.58, 1.58	]	•	ł		
Heterogeneity: Not app	olicable												
Test for overall effect:	Z = 1.55	(P =	0.12)										
Total (95% CI)			52			50	100.0%	3.58 [1.94, 5.22	1		•		
Heterogeneity: Chi <sup>2</sup> = 2	22.45, di	= 2 (	P < 0.0	0001); l²	= 91	%			100	50 1	l	+	100
Test for overall effect:	Z = 4.28	(P <	0.0001	)					-100 -	orimontal	Favoure	contro	100
Test for subgroup diffe	avours exp	ennentai	ravours	contro	Л								

Fig 17. Forest plot of effect on heart rate in the late surgical period. CI = confidence interval; IV = intravenous injection; IT = intrathecal injection; I<sup>2</sup> = heterogeneity, late = late surgical period; HR = heart rate.

#### https://doi.org/10.1371/journal.pone.0173518.g017

	adenosi	ne	contro	ols		Odds Ratio	Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% Cl	
Habib 2008	1	30	0	41	18.9%	4.22 [0.17, 107.25]		
Lee 2011	4	30	2	30	81.1%	2.15 [0.36, 12.76]		
Total (95% CI)		60		71	100.0%	2.54 [0.54, 11.98]	-	
Total events	5		2					
Heterogeneity: Chi <sup>2</sup> = 0	0.13, df = 1	(P = 0	.72); l <sup>2</sup> =			-		
Test for overall effect:	Z = 1.18 (P	= 0.24	4)	Fa	avours experimental Favours control	J		

Fig 18. Forest plot of occurrence of bradycardia.  $CI = confidence interval; I^2 = heterogeneity; M-H = Mantel-Haenszel.$ 

https://doi.org/10.1371/journal.pone.0173518.g018

this respect. The occurrence of PONV was higher in the remifentanil-treated group than in the ADO-treated group. Previous studies [18, 19] had suggested that the occurrence of PONV was associated with an increased usage of opioids. Nevertheless, our study showed no statistically significant difference between ADO and saline treatment. SBP and HR was lower in the ADO

	adenosin	ne	contro	ls		Odds Ratio	Odds Ratio			
Study or Subgroup	Events T	Total E	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI			
Habib 2008	1	30	0	41	46.8%	4.22 [0.17, 107.25]				
Lee 2011	2	30	0	30	53.2%	5.35 [0.25, 116.31]				
Total (95% CI)		60		71	100.0%	4.82 [0.52, 44.78]				
Total events	3		0							
Heterogeneity: Chi <sup>2</sup> =	0.01, df = 1 (	(P = 0.9	92); l² =			+				
Test for overall effect:	Z = 1.38 (P =	= 0.17)		Fa	vours experimental Favours control	,				

Fig 19. Forest plot of transient first degree atrio-ventricular block. CI = confidence interval; I<sup>2</sup> = heterogeneity; M-H = Mantel-Haenszel.

treated group than in the control group in the IV+ saline/mannitol subgroups throughout surgery, but in the treatment and control groups did not differ in the IT+ saline subgroup. The occurrence of bradycardia and first degree AVB did not differ statistically significantly between ADO and remiferitant treated groups.

The study of Chiari et al. [20] verified the safety of ADO, and neurological function unaffected in histopathological animal studies. In many studies, ADO has been used as ananalgesic mediator in animal and human experiments [21-25]. The present meta-analysis also showed that exogenous ADO relieved postoperative pain by 24h, thereby reducing opioid requirements. These results were in accordance with the studies by Katz et al. and Martins et al. [26, 27] in that endogenous ADO production was found to improve mechanical hyperalgesia. The first postoperative analgesic requirement was about 25 times longer than in the remifentanil subgroup. This effect was thought to be mediated throughout the nervous system by the ADO A1 receptor (A1R) [28]. ADO modulates signal transmission of pain in the periphery and the spinal cord. A1Rs can change the extracellular availability of ADO and subsequently regulate pain transmission. While the study of Sjolund et al. [25] suggested that the pain-reducing effect of ADO is due to a reduction of substance P (SP) in cerebrospinal fluid. It has been suggested that SP facilitates the excitatory amino acid-induced activation of the N-methyl D-aspartate (NMDA) via NK-1 receptor stimulation. The proposed role for SP is supported by the results of behavioral studies in which SP antagonists were used in animal models of peripheral inflammation. The study of Omoigui et al. [29] proposed that the origin of all pain is inflammation and the inflammatory response. However, the effect of ADO was only found in comparison with remifentanil and ADO, but not with saline.

The ORs of PONV in the ADO group was much lower than in the remifentanil subgroups. A study by Murataet al. [30] proposed that ADO serves to counteract further progression of hyperemesis gravidarum. Therefore, ADO seems to have a positive protective action against nausea and vomiting. In this meta-analysis, the effect was only seen in comparison between remifentanil and ADO, but not between saline and ADO.

Moreover, we found that SBP and HR of participants treated with ADO in the IV+ mannitol/saline subgroups were lower than those of the controls throughout the surgery. Thus, ADO administered by IV had marked effects on HR and BP. These effects are probably exerted through theA1, A2A, A2B, and A3 ADO receptor subtypes, which are all expressed in myocardial cells [31 32]. Activation of both the A1Rs and A2Rs is involved in the regulation of HR, whereas A3Rs play a key role in cardioprotection [32–34]. These effects reflected the classic secondary action of ADO.

Thus, ADO had the same impact as saline in terms of analgesia, but reduced heart rate and blood pressure in our meta-analysis. However, the rate of occurrence was not statistically significantly different between ADO and saline groups in terms of bradycardia and transient first- degree AVB. This may be because ADO induces the baroreceptor reflex response to hypotension and directly stimulates the sympathetic nervous system regardless of changes in blood pressure[35]. In the study by Takeshi et al. [36], almost 30% of patients demonstrated reduced heart rates after ADO infusion. This could be influenced by smoking, using the  $\beta$ -blockers, higher resting HR, lower ejection fraction, etc., both smoking and  $\beta$ -blockers might destroy the pharmacodynamics of ADO. However, higher resting HR and lower ejection fraction could be associated with the baroreceptor reflex response [35]. The studies included in our meta-analysis did not contain any information on smoking,  $\beta$ -blocker use, or ejection fraction. This should be investigated further in future.

Additionally, ADO is a powerful cardioprotective mediator in ischemic preconditioning. Any factors that are liable to increase ADO accumulation in the heart during myocardial ischemia-reperfusion would reduce myocardial injury [37]. Intracoronary ADO may be an effective therapy for no-reflow in ST-segment elevation myocardial infarction [38]. A metaanalysis by Singh et al. [39] showed that intracoronary ADO administration was well-tolerated and significantly improved electrocardiographic outcomes, with a tendency towards improvement of adverse cardiovascular events, heart failure, and cardiovascular mortality. Safety analysis showed no significant difference in chest pain events (RR 1.26, 95%CI: 0.55 to 2.86; P = 0.58), bradycardia (RR 2.19, 95%CI: 0.24 to 0.38; P = 0.49), ventricular tachycardia (OR 0.61, 95%CI:0.08 to 4.90; P = 0.64), and ventricular fibrillation (RR 0.49, 95%CI: 0.13 to 1.90; P = 0.30), as compared with the placebo group.

Furthermore, ADO activates four receptors (A1R, A2aR, A2bR, A3R) to reduce ischemiareperfusion injury, as ADO can decrease mechanical obstruction of capillaries by neutrophils. Moreover, it can block the release of vasoconstrictors (e.g.,leukotrienes, platelet activating factor, endothelin) by activated neutrophils and platelets to protect the ischemic myocardium [40]. In the study by Ernens et al. [41], ADO could stimulate increased production of thrombospondin-1 by human macrophages. In rats, chronic ADO administration can increase border-zone vascularization of myocardial infarction lesions, via increase thrombospondin-1 expression. This effect is mediated via the cAMP/PKA pathway and involves A2AR and A2BR [41]. Hence, ADO can improve cardiac function and reduce the area of myocardial infarction in multiple protective ways.

However, our meta-analysis has some limitations. We set out to perform some sensitivity analyses and subgroup analyses to assess the impact of factors on primary outcomes. These analyses may have performance, publication, or reporting bias; and the results should be considered with due caution. The small numbers of included trials was another limitation; we could not apply funnel plots and meta-regression to examine all comparisons and ORs; because these analyses were needed at least 10 studies. The small numbers of included trials caused wide CIs and ORs.

In conclusion, this meta-analysis suggested that ADO has no analgesic effect or prophylactic effect on PONV. However, ADO can reduce SBP and participants' HR in part during surgery. It did not increase the rate of occurrence of bradycardia and first- degree AVB. This may benefit patients with hypertension, ischemic heart disease (e.g.,coronary heart disease, congestive heart failure) and tachyarrhythmia(e.g.,tachycardia caused by hyperthyroidism, supraventricular tachycardia), to improve cardiac function.

#### Supporting information

**S1 Checklist. PRISMA checklist.** (DOC)

#### **Author Contributions**

Conceptualization: WM XJ. Data curation: WM XJ. Formal analysis: WM XJ. Funding acquisition: WM XJ. Investigation: WM XJ. Methodology: WM XJ. Project administration: WM XJ. Resources: WM XJ.

Software: WM XJ.

Supervision: WM XJ.

Validation: WM XJ.

Visualization: WM XJ.

Writing – original draft: XJ.

Writing - review & editing: WM.

#### References

- Apfelbaum JL, Chen C, Mehta SS, Gan TJ. Postoperative pain experience: results from a national survey suggest postoperative pain continues to be under managed. Anesthesia and analgesia 2003; 97 (2):534–40, PMID: 12873949
- Habib AS, Minkowitz H, Osborn T, Ogunnaike B, Candiotti K, Viscusi E, et al. Phase 2, double-blind, placebo-controlled, dose-responsetrial of intravenous adenosine for perioperative analgesia. Anesthesiology 2008; 109(6):1085–91 https://doi.org/10.1097/ALN.0b013e31818db88c PMID: 19034105
- Lawlor P, Frank G. High dose morphine use in the hospice setting. A database survey of patient characteristics and effect on life expectancy. Cancer 1999, 86(5):871–877 PMID: 10463988
- Dahl V, Raeder JC. Non-opioid postoperative analgesia. Acta anaesthesiologica Scandinavica 2000; 44(10):1191–203 PMID: 11065198
- Gan TJ, Habib AS. Adenosine as a non-opioid analgesic in the perioperative setting. Anesthesia and analgesia 2007; 105(2):487–94 <u>https://doi.org/10.1213/01.ane.0000267260.00384.d9</u> PMID: 17646510
- Segerdahl M, Persson E, Ekblom A, Sollevi A. Peroperative adenosine infusion reduces isoflurane concentrations during general anesthesia for shoulder surgery. Acta anaesthesiologica Scandinavica 1996; 40(7):792–7 PMID: 8874564
- 7. Segerdahl M, Irestedt L, Sollevi A. Antinociceptive effect of perioperative adenosine infusion in abdominal hysterectomy. Acta anaesthesiologica Scandinavica 1997; 41(4):473–9 PMID: 9150774
- Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Journal of clinical epidemiology 2009; 62(10):e1–34 <u>https://doi.org/10.1016/j.jclinepi.2009.06.006</u> PMID: 19631507
- Segerdahl M, Ekblom A, Sandelin K, Wickman M, Sollevi A. Peroperative adenosine infusion reduces the requirements for isoflurane and postoperative analgesics. Anesthesia and analgesia 1995; 80 (6):1145–9 PMID: 7762842
- Rane K, Sollevi A, Segerdahl M. Intrathecal adenosine administration in abdominal hysterectomy lacks analgesic effect. Acta anaesthesiologica Scandinavica 2000; 44(7):868–72 PMID: 10939701
- Apan A, Ozcan S, Buyukkocak U, Anbarci O, Basar H. Perioperative intravenous adenosine infusion to extend postoperative analgesia in brachial plexus block. European journal of anaesthesiology 2003; 20 (11):916–9 PMID: 14649345
- Apan A, Basar H, Ozcan S, Buyukkocak U. Combination of adenosine with prilocaine and lignocaine for brachial plexus block does not prolong postoperative analgesia. Anaesthesia and intensive care 2003; 31(6):648–52 PMID: 14719426
- Ghai A, Hooda S, Saxena S, Garg N, Wadhera R. Addition of adenosine to hyperbaric bupivacaine in spinal anaesthesia does not prolong postoperative analgesia in vaginal hysterectomy. South Afr J Anaesth Analg 2011; 17(4):288–92
- 14. Fukunaga AF, Alexander GE, Stark CW. Characterization of the analgesic actions of adenosine: comparison of adenosine and remifentanil infusions in patients undergoing major surgical procedures. Pain 2003; 101(1–2):129–38 PMID: 12507707
- Lee C, Song YK, Lee JH, Soo MH. The effects of intraoperative adenosine infusion on acute opioid tolerance and opioid induced hyperalgesia induced by remifentanil in adult patients undergoing tonsillectomy. The Korean journal of pain 2011; 24(1):7–12 https://doi.org/10.3344/kjp.2011.24.1.7 PMID: 21390173

- Sharma M, Mohta M, Chawla R. Efficacy of intrathecal adenosine for postoperative pain relief. European journal of anaesthesiology 2006; 23(6):449–53 https://doi.org/10.1017/S0265021506000342 PMID: 16507193
- Mishriky BM, Habib AS. Nicotine for postoperative analgesia: a systematic review and meta-analysis. Anesthesia and analgesia 2014; 119(2):268–75 https://doi.org/10.1213/ANE.0b013e3182a8fa7b PMID: 24384863
- Rawlinson A, Kitchingham N, Hart C, McMahon G, Ong SL, Khanna A. Mechanisms of reducing postoperative pain, nausea and vomiting: a systematic review of current techniques. Evidence-based medicine 2012; 17(3):75–80 https://doi.org/10.1136/ebmed-2011-100265 PMID: 22419772
- Apfel CC, Heidrich FM, Jukar-Rao S, Jalota L, Hornuss C, Whelan RP, et al. Evidence-based analysis of risk factors for postoperative nausea and vomiting. British journal of anaesthesia 2012; 109(5):742– 53 https://doi.org/10.1093/bja/aes276 PMID: 23035051
- Chiari A, Yaksh TL, Myers RR, Prvencher I, Moore L, Lee CS, et al. Preclinical toxicity screening of intrathecal adenosine in rats and dogs. Anesthesiology 1999; 91(3):824–32 PMID: 10485794
- Rane K, Sollevi A, Segerdahl M. A randomised double-blind evaluation of adenosine as adjunct to sufentanil in spinal labour analgesia. Acta anaesthesiologica Scandinavica 2003; 47(5):601–3 PMID: 12699520
- Serdiuk SE, Gmiro VE. [Peripheral acting mediators pain and analgesia potentiate the central analgesic action of fentanyl and dipyrone]. Rossiiskii fiziologicheskii zhurnal imeni IM Sechenova / Rossiiskaia akademiia nauk 2012; 98(3):325–30
- Goldman N, Chen M, Fujita T, Xu Q, Peng W, Liu W, et al. Adenosine A1 receptors mediate local antinociceptive effects of acupuncture. Nature neuroscience 2010; 13(7):883–8 https://doi.org/10.1038/nn. 2562 PMID: 20512135
- DeLander GE, Mosberg HI, Porreca F. Involvement of adenosine in antinociception produced by spinal or supraspinal receptor-selective opioid agonists: dissociation from gastrointestinal effects in mice. The Journal of pharmacology and experimental therapeutics 1992; 263(3):1097–104 PMID: 1335055
- Sjolund KF, Sollevi A, Segerdahl M, Lundeberg T. Intrathecal adenosine analog administration reduces substance P in cerebrospinal fluid along with behavioral effects that suggest antinociception in rats. Anesthesia and analgesia 1997; 85(3):627–32 PMID: 9296420
- Martins DF, Brito RN, Stramosk J, Batisti AP, Madeira F, Turnes BL, et al. Peripheral neurobiologic mechanisms of antiallodynic effect of warm water immersion therapy on persistent inflammatory pain. Journal of neuroscience research 2015; 93(1):157–66 <u>https://doi.org/10.1002/jnr.23461</u> PMID: 25079058
- Katz NK, Ryals JM, Wright DE. Central or peripheral delivery of an adenosine A1 receptor agonist improves mechanical allodynia in a mouse model of painful diabetic neuropathy. Neuroscience 2015; 285:312–23 https://doi.org/10.1016/j.neuroscience.2014.10.065 PMID: 25451280
- Abo-Salem OM, Hayallah AM, Bilkei-Gorzo A, Filipek B, Zimmer A, Muller CE. Antinociceptive effects of novel A2B adenosine receptor antagonists. The Journal of pharmacology and experimental therapeutics 2004; 308(1):358–66 https://doi.org/10.1124/jpet.103.056036 PMID: 14563788
- 29. Omoigui S. The biochemical origin of pain—proposing a new law of pain: the origin of all pain is inflammation and the inflammatory response. Part 1 of 3—a unifying law of pain. Medical hypotheses 2007; 69(1):70–82 https://doi.org/10.1016/j.mehy.2006.11.028 PMID: 17240081
- **30.** Murata T, Suzuki S, Takeuchi T, Takeshita T. Relation between plasma adenosine and serum TSH levels in women with hyperemesis gravidarum. Archives of gynecology and obstetrics 2006; 273(6):331–6 https://doi.org/10.1007/s00404-005-0091-1 PMID: 16292579
- Peart J, Flood A, Linden J, Matherne GP, Headrick JP. Adenosine-mediated cardioprotection in ischemic-reperfused mouse heart. Journal of cardiovascular pharmacology 2002; 39(1):117–29 PMID: 11743234
- Headrick JP, Willems L, Ashton KJ, Holmgren K, Peart J, Matherne GP. Ischaemic tolerance in aged mouse myocardium: the role of adenosine and effects of A1 adenosine receptor over expression. The Journal of physiology 2003; 549(Pt 3):823–33 https://doi.org/10.1113/jphysiol.2003.041541 PMID: 12717009
- Baraldi PG, Pavani MG, Shryock JC, Moorman AR, Iannotta V, Borea PA, et al. Synthesis of 2-amino-3-heteroaroylthiophenes and evaluation of their activity as potential allosteric enhancers at the human A1 receptor. European journal of medicinal chemistry 2004; 39(10):855–65 <u>https://doi.org/10.1016/j.ejmech.2004.06.009</u> PMID: 15464619
- McIntosh VJ, Lasley RD. Adenosine receptor-mediated cardioprotection: are all 4 subtypes required or redundant? Journal of cardiovascular pharmacology and therapeutics 2012; 17(1):21–33 <u>https://doi.org/10.1177/1074248410396877</u> PMID: 21335481

- 35. Dhalla AK, Wong MY, Wang WQ, Biaggioni I, Belardinelli L. Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympatho excitation in awake rats. The Journal of pharmacology and experimental therapeutics 2006; 316(2):695–702 https://doi.org/10.1124/jpet.105.095323 PMID: 16227469
- 36. Tomiyama T, Kumita S, Ishihara K, Suda M, Sakurai M, Hakzaki K, et al. Patients with reduced heart rate response to adenosine infusion have low myocardial flow reserve in (13)N-ammonia PET studies. The international journal of cardiovascular imaging 2015; 31(5):1089–95 https://doi.org/10.1007/s10554-015-0654-6 PMID: 25846547
- 37. Ihara M, Asanuma H, Yamazaki S, Kato H, Asano Y, Shinozaki Y, et al. An interaction between glucagon-like peptide-1 and adenosine contributes to cardioprotection of a dipeptidyl peptidase 4 inhibitor from myocardial ischemia-reperfusion injury. American journal of physiology Heart and circulatory physiology 2015; 308(10):H1287–97 https://doi.org/10.1152/ajpheart.00835.2014 PMID: 25747753
- Ahmed N, Layland J, Carrick D, Petrie MC, McEntegart M, Eteiba H, et al. Safety of guidewire-based measurement of fractional flow reserve and the index of microvascular resistance using intravenous adenosine in patients with acute or recent myocardial infarction. International journal of cardiology 2016; 202:305–10 https://doi.org/10.1016/j.ijcard.2015.09.014 PMID: 26418191
- Singh M, Shah T, Khosla K, Singh P, Molnar J, Khosla S, et al. Safety and efficacy of intracoronaryadenosine administration in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a meta-analysis of randomized controlled trials. Therapeutic advances in cardiovascular disease 2012; 6(3):101–14 https://doi.org/10.1177/1753944712446670 PMID: 22562999
- Gao QY, Fu Y, Hui YN. Vitreous substitutes:challenges and directions. International journal of ophthalmology 2015; 8(3):437–40 https://doi.org/10.3980/j.issn.2222-3959.2015.03.01 PMID: 26085987
- Ernens I, Bousquenaud M, Lenoir B, Devaux Y, Wagner DR. Adenosine stimulates angiogenesis by upregulating production of thrombospondin-1 by macrophages. Journal of leukocyte biology 2015; 97 (1):9–18 https://doi.org/10.1189/jlb.3HI0514-249RR PMID: 25387836